Time course for blood pressure lowering of dihydropyridine calcium channel blockers

被引:10
|
作者
Ghamami, Niousha [1 ]
Chiang, Sandy Hsiang Yu [2 ]
Dormuth, Colin [3 ]
Wright, James M. [2 ]
机构
[1] McMaster Univ, Biol & Pharmacol, 1280 Main St West, Hamilton, ON L8S 4L8, Canada
[2] Univ British Columbia, Dept Anesthesiol Pharmacol & Therapeut, Vancouver, BC V5Z 1M9, Canada
[3] Univ British Columbia, Dept Anesthesiol Pharmacol & Therapeut, Victoria, BC, Canada
基金
加拿大健康研究院;
关键词
Antihypertensive Agents [administration & dosage; therapeutic use; Blood Pressure [drug effects; physiology; Calcium Channel Blockers [therapeutic use; Circadian Rhythm; Dihydropyridines [administration & dosage; Drug Administration Schedule; Hypertension [drug therapy; Randomized Controlled Trials as Topic; Time Factors; Adult; Female; Humans; Male; GASTROINTESTINAL THERAPEUTIC SYSTEM; DOUBLE-BLIND EVALUATION; ANTIHYPERTENSIVE EFFICACY; ESSENTIAL-HYPERTENSION; OLMESARTAN MEDOXOMIL; RELEASE NICARDIPINE; 20; MG; AMLODIPINE; NITRENDIPINE; MONOTHERAPY;
D O I
10.1002/14651858.CD010052.pub2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Calcium channel blockers are a heterogeneous class of drugs, including dihydropyridine and non-dihydropyridine subgroups, commonly used in the treatment of hypertension. A systematic review of the 24-hour time course of the blood pressure-lowering effect has not been published. Objectives To assess how much variation there is in hourly systolic and diastolic blood pressure lowering by dihydropyridine calcium channel blockers over a 24-hour period in people with hypertension aged 18 years or over, with baseline systolic blood pressure of at least 140 mmHg or diastolic blood pressure of at least 90 mmHg, or both. Search methods We performed electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 1, 2014), MEDLINE (1946 to February 2014), EMBASE (1974 to February 2014), and ClinicalTrials.gov (to February 2014). We also screened references of published studies and reviews to identify additional trials. Selection criteria We included all randomized, placebo-controlled trials assessing the hourly effects of dihydropyridine calcium channel blockers by ambulatory blood pressure monitoring in adults with hypertension with a follow-up of at least three weeks. Data collection and analysis Two authors independently selected the included trials, evaluated the risk of bias, and analyzed the data. Main results We included 16 randomized controlled trials of dihydropyridine calcium channel blockers in this systematic review, with 2768 randomized participants. Drugs studied included amlodipine, lercanidipine, mandipine, nifedipine, and felodipine (all administered once daily) and nicardipine (administered twice daily). We analyzed and presented data by hour post dose. The blood pressure-lowering effect was stable over time; there were no clinically important differences in blood pressure-lowering effect of calcium channel blockers between each hour for either systolic blood pressure (estimated mean hourly differences ranged between 9.45 mmHg and 13.2 mmHg) or diastolic blood pressure (estimated mean hourly differences ranged between 5.85 mmHg and 8.5 mmHg). However, there was a moderate risk of bias for this finding. Once-daily dihydropyridine calcium channel blockers appeared to lower blood pressure by a relatively constant amount throughout the 24-hour dosing interval. Authors' conclusions Six dihydropyridine calcium channel blockers studied in this review lowered blood pressure by a relatively similar amount each hour over the course of 24 hours. The benefits and harms of this pattern of blood pressure lowering are unknown. Further trials are needed with accurate recording of time of drug intake and with reporting of standard deviation of blood pressure at each hour. We did not attempt to assess adverse effects in this review due to the lack of reporting and the short duration of follow-up.
引用
收藏
页数:68
相关论文
共 50 条
  • [1] Blood Pressure-Lowering Profiles and Clinical Effects of Angiotensin Receptor Blockers Versus Calcium Channel Blockers
    Mehlum, Maria H.
    Liestol, Knut
    Kjeldsen, Sverre E.
    Wyller, Torgeir B.
    Julius, Stevo
    Rothwell, Peter M.
    Mancia, Giuseppe
    Parati, Gianfranco
    Weber, Michael A.
    Berge, Eivind
    HYPERTENSION, 2020, 75 (06) : 1584 - 1592
  • [2] Time course for blood pressure lowering of beta-blockers with partial agonist activity
    Zhang, Xiao-Yin
    Soufi, Sam
    Dormuth, Colin
    Musini, Vijaya M.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2020, (09):
  • [3] Effect of dihydropyridine calcium channel blockers on blood pressure variability in the SPRINT trial: a treatment effects approach
    de Havenon, Adam
    Petersen, Nils
    Wolcott, Zoe
    Goldstein, Eric
    Delic, Alen
    Sheibani, Nazanin
    Anadani, Mohammad
    Sheth, Kevin N.
    Lansberg, Maarten
    Turan, Tanya
    Prabhakaran, Shyam
    JOURNAL OF HYPERTENSION, 2022, 40 (03) : 462 - 469
  • [4] Dihydropyridine calcium channel blockers and renal disease
    Robles, Nicolas R.
    Fici, Francesco
    Grassi, Guido
    HYPERTENSION RESEARCH, 2017, 40 (01) : 21 - 28
  • [5] NEW DIHYDROPYRIDINE CALCIUM-CHANNEL BLOCKERS
    KOROLKOVAS, A
    DEARAUJO, MB
    LIMA, F
    REVISTA BRASILEIRA DE MEDICINA, 1991, 48 (09) : 597 - &
  • [6] Dihydropyridine Calcium Channel Blockers and Kidney Outcomes
    Blum, Matthew F.
    Surapaneni, Aditya
    Chang, Alexander
    Inker, Lesley A.
    Chen, Teresa K.
    Appel, Lawrence J.
    Shin, Jung-Im
    Grams, Morgan E.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2024, 39 (10) : 1880 - 1886
  • [7] Dihydropyridine Calcium Channel Blockers and Incident Albuminuria
    Blum, Matthew F.
    Surapaneni, Aditya L.
    Chang, Alex R.
    Inker, Lesley A.
    Shin, Jung-Im
    Grams, Morgan
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 528 - 528
  • [8] Dihydropyridine calcium channel blockers and renal disease
    Nicolás R Robles
    Francesco Fici
    Guido Grassi
    Hypertension Research, 2017, 40 : 21 - 28
  • [9] Perioperative use of dihydropyridine calcium channel blockers
    Poelaert, J
    Roosens, C
    ACTA ANAESTHESIOLOGICA SCANDINAVICA, 2000, 44 (05) : 528 - 535
  • [10] Dihydropyridine Calcium Channel Blockers and the Progression of Parkinsonism
    Marras, Connie
    Gruneir, Andrea
    Rochon, Paula
    Wang, Xuesong
    Anderson, Geoff
    Brotchie, Jonathan
    Bell, Chaim M.
    Fox, Susan
    Austin, Peter C.
    ANNALS OF NEUROLOGY, 2012, 71 (03) : 362 - 369